Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Recruiting · NCT06927635 · Interventional (participants receive a specific treatment) · Lead sponsor: University Health Network, Toronto
View the official record on ClinicalTrials.gov →Interventions studied
Stereotactic Body Radiation Therapy (SBRT)Systemic therapy
What this trial is about
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
Who can take part
Age range
18 Years to 100 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age \>18 years
- Able to provide informed consent
- Histologic diagnosis of prostate adenocarcinoma
- Castrate Resistance Prostate Cancer
- Radiographic evidence of \<10 sites of extra-cranial OP metastatic lesions
- Receiving any line of ST for \>3 months
- All sites of OP disease are amenable to and can be safely treated with SBRT
- ECOG performance status 0-3
Exclusion criteria
- Evidence of spinal cord compression
- Contraindication to radiotherapy
Where it is running
1 location listed.
- Princess Margaret Cancer Center - Toronto, Ontario, Canada